5) Intervention in HCM: patient selection, procedural approach and emerging techniques in alcohol septal ablation. Cooper RM, Shahzad A, Stables RH. Echo Res Pract . 2015;2(1):R25‐R35. doi:10.1530/ERP-14-0058
6) A prospective follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy–the Baylor experience (1996-2002). Fernandes VL, Nagueh SF, Wang W, Roberts R, Spencer WH 3rd.Clin Cardiol . 2005;28(3):124‐130. doi:10.1002/clc.4960280305
7) Hypertrophic Obstructive Cardiomyopathy. Batzner A, Schäfers HJ, Borisov KV, Seggewiß H. Dtsch Arztebl Int . 2019;116(4):47‐53. doi:10.3238/arztebl.2019.0047
8) Alcohol septal ablation in hypertrophic cardiomyopathy. Mateo JJS, Gimeno JR. Glob Cardiol Sci Pract . 2018;2018(3):30. Published 2018 Aug 12. doi:10.21542/gcsp.2018.30
9) How Symptomatic Should a Hypertrophic Obstructive Cardiomyopathy Patient Be to Consider Alcohol Septal Ablation?. Jones BM, Krishnaswamy A, Smedira NG, Desai MY, Tuzcu EM, Kapadia SR. J Am Heart Assoc . 2017;6(5):e006292. Published 2017 May 16. doi:10.1161/JAHA.117.006292
10) Short- and long-term outcome after alcohol septal ablation in obstructive hypertrophic cardiomyopathy: Experience of a reference center. Aguiar Rosa S, Fiarresga A, Galrinho A, Cacela D, Ramos R, de Sousa L et al. Rev Port Cardiol. 2019 Jul;38(7):473-480. doi: 10.1016/j.repc.2019.08.003. Epub 2019 Sep 5. doi:10.1016/j.repc.2019.08.003
11) Procedural complication and long term outcomes after alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: data from China. An SY, Yang YJ, Hang F, Wang ZM, Fan CM. Sci Rep . 2017;7(1):9506. Published 2017 Aug 25. doi:10.1038/s41598-017-10144-0
12) 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Authors./Task Force members, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F et al. Eur Heart J. 2014 Oct 14;35(39):2733-79. doi: 10.1093/eurheartj/ehu284. Epub 2014 Aug 29.
13) Outcome of Alcohol Septal Ablation in Mildly Symptomatic Patients With Hypertrophic Obstructive Cardiomyopathy: A Long-Term Follow-Up Study Based on the Euro-Alcohol Septal Ablation Registry. Veselka J, Faber L, Liebregts M, et al. J Am Heart Assoc . 2017;6(5):e005735. Published 2017 May 16. doi:10.1161/JAHA.117.005735
14) Results of Ten-Year Follow-Up of Alcohol Septal Ablation in Patients with Obstructive Hypertrophic Cardiomyopathy. Kashtanov M, Rzhannikova A, Chernyshev S, Kardapoltsev L, Idov E, Berdnikov S. Int J Angiol . 2018;27(4):202‐207. doi:10.1055/s-0038-1675213
15) Outcome of patients ≥ 60 years of age after alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Jahnlová D, Tomašov P, Adlová R, et al. Arch Med Sci . 2019;15(3):650‐655. doi:10.5114/aoms.2019.84735
16) Percutaneous septal ablation for left mid-ventricular obstructive hypertrophic cardiomyopathy: a case report. Tengiz I, Ercan E, Alioglu E, Turk UO. BMC Cardiovasc Disord . 2006;6:15. Published 2006 Apr 10. doi:10.1186/1471-2261-6-15
17) Rescue alcohol septal ablation in sepsis with multiorgan failure. Barwad PW, Ramakrishnan S, Seth S, Bhargava B. Indian Heart J . 2012;64(6):588‐590. doi:10.1016/j.ihj.2012.09.004
18) SUCCESSFUL PERCUTANEOUS SEPTAL ALCOHOL ABLATION AFTER SURGICAL MYECTOMY. Kulić M, Spužić M, Tahirović E, et al. Bosn J Basic Med Sci . 2010;10(3):216‐222.
19) Comparison of long-term effect of dual-chamber pacing and alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy. Krejci J, Gregor P, Zemanek D, et al.ScientificWorldJournal . 2013;2013:629650. Published 2013 Nov 11. doi:10.1155/2013/629650
20) Results of surgical septal myectomy for obstructive hypertrophic cardiomyopathy: the Tufts experience. Rastegar H, Boll G, Rowin EJ, et al. Ann Cardiothorac Surg . 2017;6(4):353‐363. doi:10.21037/acs.2017.07.07
21) Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. Xin J, Shiota T, Lever HM, Kapadia SR, Sitges M, Rubin DN et al. J Am Coll Cardiol. 2001 Dec, 38 (7) 1994-2000. doi: 10.1016/S0735-1097(01)01656-4
22) Long-term clinical and echocardiographic outcomes of extensive septal myectomy for hypertrophic obstructive cardiomyopathy in Chinese patients. Yao L, Li L, Lu XJ, Miao YL, Kang XN, Duan FJ.Cardiovasc Ultrasound . 2016;14(1):18. Published 2016 May 17. doi:10.1186/s12947-016-0060-9
23) Septal myotomy–myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy. A comparison of clinical, haemodynamic and exercise outcomes. Firoozi S, Elliott PM, Sharma S, Murday A, Brecker SJ, Hamid MS et al Eur Heart J. 2002 Oct;23(20):1617-24. Doi:10.1053/euhj.2002.3285
24) Electrocardiographic changes after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Kazmierczak J, Kornacewicz-Jach Z, Kisly M, Gil R, Wojtarowicz A. Heart . 1998;80(3):257‐262. doi:10.1136/hrt.80.3.257
25) Alcohol septal ablation for hypertrophic obstructive cardiomyopathy - 8 years follow up. Sathyamurthy I, Nayak R, Oomman A, et al.Indian Heart J . 2014;66(1):57‐63. doi:10.1016/j.ihj.2013.12.008
26) Prognostic significance of repeated brain natriuretic peptide measurements after percutaneous transluminal septal myocardial ablation in patients with drug-refractory hypertrophic obstructive cardiomyopathy. Akita K, Tsuruta H, Yuasa S, Murata M, Fukuda K, Maekawa Y. Open Heart . 2018;5(1):e000786. Published 2018 May 10. doi:10.1136/openhrt-2018-000786
27) Pathological effects of alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Baggish AL, Smith RN, Palacios I, et al.Heart . 2006;92(12):1773‐1778. doi:10.1136/hrt.2006.092007
28) Predictors of outcome after alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy. Special interest for the septal coronary anatomy. Steggerda RC, Balt JC, Damman K, van den Berg MP, Ten Berg JM. Neth Heart J . 2013;21(11):504‐509. doi:10.1007/s12471-013-0453-4
29) Alcohol Septal Ablation for the Treatment of Hypertrophic Obstructive Cardiomyopathy. A Multicenter North American Registry. Nagueh SF, Groves BM, Schwartz L, Smith KM, Wang A, Bach RG. J Am Coll Cardiol. 2011 Nov, 58 (22) 2322-2328. DOI: 10.1016/j.jacc.2011.06.073
30) Implantable Cardioverter-Defibrillator Therapy for Primary Prevention of Sudden Death After Alcohol Septal Ablation of Hypertrophic Cardiomyopathy. Cuoco FA, Spender WH 3rd, Fernandes VL, Nielsen CD, Nagueh SF, Sturdivant JL et al. J Am Coll Cardiol. 2008 Nov, 52 (21) 1718-1723. DOI: 10.1016/j.jacc.2008.07.061
31) Temporal Occurrence of Arrhythmic Complications After Alcohol Septal Ablation. El-Sabawi B, Nishimura RA, Barsness GW, Cha YM, Geske JB, Eleid MF. Circ Cardiovasc Interv. 2020 Feb;13(2):e008540. doi: 10.1161/CIRCINTERVENTIONS.119.008540.
32) Incidence of Atrial Fibrillation following Alcohol Septal Ablation for Hypertrophic Cardiomyopathy. Moss TJ, Zipse MM, Krantz MJ, Sauer WH, Salcedo EE, Schuller JL. Ann Noninvasive Electrocardiol . 2016;21(5):443‐449. doi:10.1111/anec.12335
33) Visualization of transcoronary ablation of septal hypertrophy in patients with hypertrophic obstructive cardiomyopathy: a comparison between cardiac MRI, invasive measurements and echocardiography. Sohns C, Sossalla S, Schmitto JD, et al. Clin Res Cardiol . 2010;99(6):359‐368. doi:10.1007/s00392-010-0128-8
34) Percutaneous Septal Ablation in Hypertrophic Obstructive Cardiomyopathy: From Experiment to Standard of Care. Faber L. Adv Med . 2014;2014:464851. doi:10.1155/2014/464851
35) Twenty Years of Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy. Rigopoulos AG, Seggewiss H. Curr Cardiol Rev . 2016;12(4):285‐296. doi:10.2174/1573403x11666150107160344
36) Alcohol septal ablation: in which patients and why?. Spirito P, Rossi J, Maron BJ. Ann Cardiothorac Surg . 2017;6(4):369‐375. doi:10.21037/acs.2017.05.09
37) hypertrophic cardiomyopathy: preliminary attempt at palliation with use of subselective alcohol ablation. Angelini P, Uribe C, Monge J, Escobar JM, Hernandez-Vila E. Apical Tex Heart Inst J . 2012;39(5):750‐755.
38) Genetics of hypertrophic cardiomyopathy: advances and pitfalls in molecular diagnosis and therapy. Roma-Rodrigues C, Fernandes AR.Appl Clin Genet . 2014;7:195‐208. Published 2014 Oct 3. doi:10.2147/TACG.S49126
39) Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Wigle ED, Rakowski H, Kimball BP, Williams WG. Circulation. 1995 Oct 1;92(7):1680-92. doi:10.1161/01.cir.92.7.1680
40) Hypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction. Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT et al. Circulation. 2006;114:2232–2239. https://doi.org/10.1161/CIRCULATIONAHA.106.644682
41) Regression of Left Ventricular Hypertrophy After Nonsurgical Septal Reduction Therapy for Hypertrophic Obstructive Cardiomyopathy. Mazur W, Nagueh SF, Lakkis NM, Middleton KJ, Killip D, Roberts R et al. Circulation. 2001;103:1492–1496. Doi:10.1161/01.cir.103.11.1492
42) Predictors of Outcome After Alcohol Septal Ablation Therapy in Patients With Hypertrophic Obstructive Cardiomyopathy. Chang SM, Lakkis NM, Franklin J, Spencer WH 3rd, Nagueh SF. Circulation. 2004 Feb 24;109(7):824-7. Epub 2004 Feb 16. doi:10.1161/01.CIR.0000117089.99918.5A
43) Comparison of Surgical Septal Myectomy and Alcohol Septal Ablation With Cardiac Magnetic Resonance Imaging in Patients With Hypertrophic Obstructive Cardiomyopathy. Valeti US, Nishimura RA, Holmes DR, Araoz PA, Glockner JF, Breen JF et al. J Am Coll Cardiol. 2007 Jan, 49 (3) 350-357. doi: 10.1016/j.jacc.2006.08.055
44) Sustained improvement in left ventricular diastolic function after alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Jassal DS, Neilan TG, Fifer MA, Palacios IF, Lowry PA, Vlahakes GJ et al. Eur Heart J. 2006 Aug;27(15):1805-10. Epub 2006 Jun 14. Doi:10.1093/eurheartj/ehl106
45) Periprocedural Complications and Long-Term Outcome After Alcohol Septal Ablation Versus Surgical Myectomy in Hypertrophic Obstructive Cardiomyopathy. A Single-Center Experience. Steggerda RC, Damman K, Balt JC, Liebregts M, ten Berg JM, van den Berg M. J Am Coll Cardiol Intv. 2014 Nov, 7 (11) 1227-1234. DOI: 10.1016/j.jcin.2014.05.023
46) Myectomy versus alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy. Afanasyev A, Bogachev-Prokophiev AV, Kashtanov MG, Astapov D, Zalesov AS, Budagaev SA et al. Interactive CardioVascular and Thoracic Surgery . https://doi.org/10.1093/icvts/ivaa075
47) Cardiomyopathy: The diagnosis of hypertrophic cardiomyopathy. Wigle ED. Heart . 2001;86(6):709‐714. doi:10.1136/heart.86.6.709
48) Alcohol septal ablation versus surgical septal myectomy: comparison of effects on atrioventricular conduction tissue. Talreja DR, Nishimura RA, Edwards WD, Valeti US, Ommen SR, Tajik AJ et al. J Am Coll Cardiol. 2004 Dec 21;44(12):2329-32. DOI:10.1016/j.jacc.2004.09.036
49) Effects of alcohol septal ablation on coronary microvascular function and myocardial energetics in hypertrophic obstructive cardiomyopathy. Timmer SA, Knaapen P, Germans T, Dijkmans PA, Lubberink M, Ten Berg JM et al. Am J Physiol Heart Circ Physiol. 2011 Jul;301(1):H129-37. doi: 10.1152/ajpheart.00077.2011. Epub 2011 Apr 13